-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 13th, Tonghua Dongbao issued an announcement stating that the company submitted on March 28, 2021, the company submitted a type II communication regarding the parallel implementation of phase III clinical trials and phase I clinical trials of super fast-acting insulin lispro injection (THDB0206) in China.
On April 26, 2018, Tonghua Toho and SAADOCIA (hereinafter referred to as "Adocia") signed the "Super Fast-acting Insulin Cooperation and Licensing Agreement".
Tonghua Dongbao began technology transfer and further development in May 2018.
In June and July 2020, Tonghua Toho’s partner Adocia was successively approved by the German Food and Drug Administration BfArM and the US FDA to initiate phase I PK/PD clinical trials, and obtain the trial report in January 2021
As of the date of this announcement, the company has invested approximately RMB 47,718,800 in research and development expenses in this project
Super fast-acting insulin lispro injection (THDB0206) belongs to a new generation of fast-acting insulin analogues.
